Journal Home > Volume 1 , Issue 1
Journal of Neurorestoratology 2013, 1(1): 23-29 https://doi.org/10.2147/JN.S47273
Short Report | Open Access | Issue | Published: 19 August 2013

Human umbilical cord blood mononuclear cell transplantation for delayed encephalopathy after carbon monoxide intoxication

Show Author's Information Dianrong Gong1,  Haiyan Yu1,  Weihua Wang2,  Haixin Yang1,  Fabin Han1,2( )
Department of Neurology,
Centre for Stem Cells and Regenerative Medicine, Liaocheng People’s Hospital, The Affiliated Liaocheng Hospital, Taishan Medical University, Shandong, People’s Republic of China
Keywords:
transplantation, human umbilical cord blood mononuclear cells, delayed encephalopathy after carbon monoxide intoxication, MMSE
Cite this article:
Gong D, Yu H, Wang W, et al. Human umbilical cord blood mononuclear cell transplantation for delayed encephalopathy after carbon monoxide intoxication. Journal of Neurorestoratology, 2013, 1(1): 23-29. https://doi.org/10.2147/JN.S47273
Download citation
EndNote(RIS)
BibTeX

327

Views

8

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Stem cell transplantation is one of the potential treatments for neurological disorders. Since human umbilical cord stem cells have been shown to provide neuroprotection and promote neural regeneration, we have attempted to transplant the human umbilical cord blood mononuclear cells (hUCB-MNCs) to treat patients with delayed encephalopathy after carbon monoxide intoxication (DEACOI). The hUCB-MNCs were isolated from fresh umbilical cord blood and were given to patients subarachnoidally. Physical examinations, mini-mental state examination scores, and computed tomography scans were used to evaluate the improvement of symptoms, signs, and pathological changes of the patient’s brain before and after hUCB-MNC transplantation. A total of 12 patients with DEACOI were treated with hUCB-MNCs in this study. We found that most of the patients have shown significant improvements in movement, behavior, and cognitive function, and improved brain images in 1–4 months from the first transplantation of hUCB-MNCs. None of these patients have been observed to have any severe adverse effects. Our study suggests that the hUCB-MNC transplantation may be a safe and effective treatment for DEACOI. Further studies and clinical trials with more cases, using more systematic scoring methods, are needed to evaluate brain structural and functional improvements in patients with DEACOI after hUCB-MNC therapy.


menu
Abstract
Full text
Outline
About this article

Human umbilical cord blood mononuclear cell transplantation for delayed encephalopathy after carbon monoxide intoxication

Show Author's information Dianrong Gong1, Haiyan Yu1, Weihua Wang2, Haixin Yang1, Fabin Han1,2( )
Department of Neurology,
Centre for Stem Cells and Regenerative Medicine, Liaocheng People’s Hospital, The Affiliated Liaocheng Hospital, Taishan Medical University, Shandong, People’s Republic of China

Abstract

Stem cell transplantation is one of the potential treatments for neurological disorders. Since human umbilical cord stem cells have been shown to provide neuroprotection and promote neural regeneration, we have attempted to transplant the human umbilical cord blood mononuclear cells (hUCB-MNCs) to treat patients with delayed encephalopathy after carbon monoxide intoxication (DEACOI). The hUCB-MNCs were isolated from fresh umbilical cord blood and were given to patients subarachnoidally. Physical examinations, mini-mental state examination scores, and computed tomography scans were used to evaluate the improvement of symptoms, signs, and pathological changes of the patient’s brain before and after hUCB-MNC transplantation. A total of 12 patients with DEACOI were treated with hUCB-MNCs in this study. We found that most of the patients have shown significant improvements in movement, behavior, and cognitive function, and improved brain images in 1–4 months from the first transplantation of hUCB-MNCs. None of these patients have been observed to have any severe adverse effects. Our study suggests that the hUCB-MNC transplantation may be a safe and effective treatment for DEACOI. Further studies and clinical trials with more cases, using more systematic scoring methods, are needed to evaluate brain structural and functional improvements in patients with DEACOI after hUCB-MNC therapy.

Keywords: transplantation, human umbilical cord blood mononuclear cells, delayed encephalopathy after carbon monoxide intoxication, MMSE

References(35)

1.
O’Donnell P, Buxton PJ, Pitkin A, Jarvis LJ. The magnetic resonance imaging appearances of the brain in acute carbon monoxide poisoning. Clin Radiol. 2000;55(4):273–280.
DOI Google Scholar
2.
Kawanami T, Kato T, Kurita K, Sasaki H. The pallidoreticular pattern of brain damage on MRI in a patient with carbon monoxide poisoning. J Neurol Neurosurg Psychiatr. 1998;64(2):282.
DOI Google Scholar
3.
Kamada K, Houkin K, Aoki T, et al. Cerebral metabolic changes in delayed carbon monoxide sequelae studied by proton MR spectroscopy. Neuroradiology. 1994;36(2):104–106.
DOI Google Scholar
4.
Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;11(1):26–34.
DOI Google Scholar
5.
Borlongan CV. Recent preclinical evidence advancing cell therapy for Alzheimer’s disease. Exp Neurol. 2012;237(1):142–146.
DOI Google Scholar
6.
Yasuhara T, Matsukawa N, Hara K, et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci. 2006;26(48):12497–12511.
DOI Google Scholar
7.
Ebert AD, Beres AJ, Barber AE, Svendsen CN. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson’s disease. Exp Neurol. 2008;209(1): 213–223.
DOI Google Scholar
8.
Kim HJ, McMillan E, Han F, Svendsen CN. Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. Stem Cells. 2009;27(2):390–398.
DOI Google Scholar
9.
Schwinger W, Urban C, Lackner H, et al. Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 1998;22(4):393–396.
DOI Google Scholar
10.
Pimentel-Coelho PM, Rosado-de-Castro PH, da Fonseca LM, Mendez-Otero R. Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatr Res. 2012;71(4 Pt 2):464–473.
DOI Google Scholar
11.
Ende N, Chen R. Parkinson’s disease mice and human umbilical cord blood. J Med. 2002;33(1–4):173–180.
Google Scholar
12.
Mathieu P, Roca V, Gamba C, Del Pozo A, Pitossi F. Neuroprotective effects of human umbilical cord mesenchymal stromal cells in an immunocompetent animal model of Parkinson’s disease. J Neuroimmunol. 2012;246(1–2):43–50.
DOI Google Scholar
13.
Ende N, Chen R, Ende-Harris D. Human umbilical cord blood cells ameliorate Alzheimer’s disease in transgenic mice. J Med. 2001;32(3-4): 241–247.
Google Scholar
14.
Garbuzova-Davis S, Willing AE, Zigova T, et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003;12(3):255–270.
DOI Google Scholar
15.
Sanberg PR, Eve DJ, Willing AE, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20(1):85–94.
DOI Google Scholar
16.
Kim JY, Kim DH, Kim JH, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ. 2012;19(4):680–691.
DOI Google Scholar
17.
Lee HJ, Lee JK, Lee H, et al. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer’s disease. Neurosci Lett. 2010;481(1):30–35.
DOI Google Scholar
18.
Riegelsberger UM, Deten A, Pösel C, et al. Intravenous human umbilical cord blood transplantation for stroke: impact on infarct volume and caspase-3-dependent cell death in spontaneously hypertensive rats. Exp Neurol. 2011;227(1):218–223.
DOI Google Scholar
19.
Hopkins RO, Woon FL. Neuroimaging, cognitive, and neurobehavioral outcomes following carbon monoxide poisoning. Behav Cogn Neurosci Rev. 2006;5(3):141–155.
DOI Google Scholar
20.
Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer' s disease. Curr Med Res Opin. 2002;18(6):347–354.
DOI Google Scholar
21.
Newman MB, Davis CD, Borlongan CV, Emerich D, Sanberg PR. Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin Biol Ther. 2004;4(2):121–130.
DOI Google Scholar
22.
Li X, Li H, Bi J, Chen Y, Jain S, Zhao Y. Human cord blood-derived multipotent stem cells (CB-SCs) treated with all-trans-retinoic acid (ATRA) give rise to dopamine neurons. Biochem Biophys Res Commun. 2012;419(1):110–116.
DOI Google Scholar
23.
Slovinska L, Novotna I, Kubes M, et al. Umbilical cord blood cells CD133+/CD133-cultivation in neural proliferation media differentiates towards neural cell lineages. Arch Med Res. 2011;42(7):555–562.
DOI Google Scholar
24.
Khoo ML, Tao H, Meedeniya AC, Mackay-Sim A, Ma DD. Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One. 2011;6(5):e19025.
DOI Google Scholar
25.
Newcomb JD, Ajmo CT, Sanberg CD, Sanberg PR, Pennypacker KR, Willing AE. Timing of cord blood treatment after experimental stroke determines therapeutic efficacy. Cell Transplant. 2006;15(3): 213–223.
DOI Google Scholar
26.
Lee HJ, Lee JK, Lee H, et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging. 2012;33(3):588–602.
DOI Google Scholar
27.
Jiang L, Womble T, Saporta S, et al. Human umbilical cord blood cells decrease microglial survival in vitro. Stem Cells Dev. 2010;19(2): 221–228.
DOI Google Scholar
28.
Yuan T, Liao W, Feng NH, et al. Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurological function in a rat model of middle cerebral artery occlusion. Stem Cell Res Ther. 2013;4(3):73.
DOI Google Scholar
29.
Park DH, Borlongan CV, Willing AE, et al. Human umbilical cord blood cell grafts for brain ischemia. Cell Transplant. 2009;18(9):985–998.
DOI Google Scholar
30.
Barker RA. Stem cells and neurodegenerative diseases: where is it all going? Regen Med. 2012;7(6 Suppl):26–31.
DOI Google Scholar
31.
Martínez-Morales PL, Revilla A, Ocaña I, et al. Progress in Stem Cell Therapy for Major Human Neurological Disorders. Stem Cell Rev. Epub 2013 May 17.
Google Scholar
32.
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858): 1917–1920.
DOI Google Scholar
33.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5): 861–872.
DOI Google Scholar
34.
Soldner F, Hockemeyer D, Beard C, et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136(5):964–977.
DOI Google Scholar
35.
Jung YW, Hysolli E, Kim KY, Tanaka Y, Park IH. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. Curr Opin Neurol. 2012;25(2):125–130.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Published: 19 August 2013
Issue date: December 2013

Copyright

© 2013 The Author(s).

Rights and permissions

© 2013 Gong et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Ltd. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Return